← Pipeline|Zoriosocimab

Zoriosocimab

Approved
AKR-1543
Source: Trial-derived·Trials: 1
Modality
Gene Therapy
MOA
TROP-2 ADC
Target
C5
Pathway
Wnt
MCCNBCKD
Development Pipeline
Preclinical
~Apr 2011
~Jul 2012
Phase 1
~Oct 2012
~Jan 2014
Phase 2
~Apr 2014
~Jul 2015
Phase 3
~Oct 2015
~Jan 2017
NDA/BLA
~Apr 2017
~Jul 2018
Approved
Oct 2018
Nov 2030
ApprovedCurrent
NCT03848008
1,865 pts·NB
2018-102030-11·Terminated
1,865 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-11-114.6y awayPh3 Readout· NB
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2030-11-11 · 4.6y away
NB
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03848008ApprovedNBTerminated1865eGFR
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-9749Eli LillyPhase 3C5FGFRi
LLY-1184Eli LillyNDA/BLAC5CD3xCD20
RHH-1546RochePhase 2/3C5CAR-T CD19
BAY-6035BayerPhase 1C5Anti-Aβ
BAY-6520BayerPhase 2AHRTROP-2 ADC
BemazumabRegeneronPhase 1VEGFTROP-2 ADC
ARG-1250ArgenxPhase 2C5GLP-1ag
GMA-5010GenmabPhase 3JAK2TROP-2 ADC
INC-1582IncytePhase 1/2APOC3TROP-2 ADC
ElratapinarofHalozymePhase 2C5AHRant